Most important cardiotoxicity of immune checkpoint inhibitors – Cardiology MCQ

Most important cardiotoxicity of immune checkpoint inhibitors – Cardiology MCQ

Cardiotoxicity of antineoplastic drugs like adriamycin is well known. In fact regular monitoring and management of cardiotoxicity of antineoplastic drugs have given rise to a new subspeciality known as Onco Cardiology [1]. Immune checkpoint inhibitors are novel anti cancer drugs targeting immune checkpoint molecules: cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and its ligand (PD-L1) [2]. They are highly useful in a large number of solid and hematological tumours, otherwise associated with a poor prognosis. They are distinct from targeted therapies and tumour type specific therapies.
The most important recently highlighted immune checkpoint inhibitor cardiotoxicity is:

1. Fulminant myocarditis
2. Acute myocardial infarction
3. QT prolongation
4. Venous thromboembolism

Please click here for the correct answer

Reference

1. Sueta D, Hokimoto S. Onco-cardiology: Present and future. Int J Cardiol. 2016 Jul 15;215:38-40.
2. Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, Marone G, Tocchetti CG. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017 Oct 26;2(4):e000247.